Tokai Hopes To Move $97M Suit Over IPO To Mass. Fed. Court

Law360, New York (December 20, 2016, 6:30 PM EST) -- Tokai Pharmaceuticals Inc. Monday sought to move a putative class action by investors claiming it withheld important drug testing information prior to its $97 million initial public offering to a Massachusetts federal court Monday.

The suit, filed by investor Hao Wu in Massachusetts state court two weeks ago, claims the company failed to properly test the prostate cancer drug it was developing and its IPO underwriters did not warn investors of this, causing them to be blindsided when the drug failed and the stock plunged.

“As a result of these disclosures, at the time of the filing of this action, Tokai...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!